Search
Abexinostat
go.drugbank.com/drugs/DB12565InvestigationalAbexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. … It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.
Tetrahydrocannabivarin
go.drugbank.com/drugs/DB11755InvestigationalΔ9-THC is currently available in several synthetic forms, including [Dronabinol], while purified or isolated THCV is not approved for any medical uses and is not available as any marketed products. … Further evidence has also shown that THCV acts as an agonist of GPR55 and l-α-lysophosphatidylinositol (LPI) [A32974].
Ebiratide
go.drugbank.com/drugs/DB20555ExperimentalEbiratide is a small molecule drug. Ebiratide has a monoisotopic molecular weight of 995.53 Da.
Categories: Pro-OpiomelanocortinSRP-9005
go.drugbank.com/drugs/DB17958InvestigationalSRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. … Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]
Rintodestrant
go.drugbank.com/drugs/DB21472InvestigationalRintodestrant has a monoisotopic molecular weight of 462.09 Da. … Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).
Oleic monoethanolamide
go.drugbank.com/drugs/DB16495InvestigationalSynonyms: N-OEA, N-oleoylethanolamineCategories: Experimental Unapproved Treatments for COVID-19Tralesinidase alfa
go.drugbank.com/drugs/DB17657InvestigationalTralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2. … It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.[A258828]
Synonyms: Alpha-N-acetyglucosaminidase-insulin-like-growth-factor-2 fusion protein, Recombinant human alpha-N-acetylglucosaminidase-insulin-like growth factor-2Categories: beta-N-AcetylhexosaminidasesNSI-566
go.drugbank.com/drugs/DB17954InvestigationalNSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. … Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]
Drozitumab
go.drugbank.com/drugs/DB19106InvestigationalIt was developed by Genentech as a drug for the treatment of cancers … Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL)
Synonyms: Immunoglobulin g1, anti-(human citokine receptor dr5 (death receptor 5)) (human monoclonal heavy chain), disulfide with human l3-chain, dimerAdecatumumab
go.drugbank.com/drugs/DB05006InvestigationalEpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. … Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM).